|
C20ORF111 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.7377210781433E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.0522472610196E-12 |
| Normal-vs-Stage2 |
1.64512847788956E-12 |
| Normal-vs-Stage3 |
3.66373598126302E-15 |
| Normal-vs-Stage4 |
5.77315972805081E-14 |
| Stage1-vs-Stage2 |
2.533600E-01 |
| Stage1-vs-Stage3 |
4.991400E-01 |
| Stage1-vs-Stage4 |
2.055800E-01 |
| Stage2-vs-Stage3 |
6.061800E-01 |
| Stage2-vs-Stage4 |
9.571800E-01 |
| Stage3-vs-Stage4 |
4.984200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.72066830070617E-13 |
| Normal-vs-AfricanAmerican |
1.27389999993177E-07 |
| Normal-vs-Asian |
1.93200011544548E-10 |
| Caucasian-vs-AfricanAmerican |
9.626000E-01 |
| Caucasian-vs-Asian |
6.966800E-01 |
| AfricanAmerican-vs-Asian |
7.587000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.25441887380384E-12 |
| Normal-vs-Female |
8.870681966755E-14 |
| Male-vs-Female |
6.243600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.66875410659395E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
2.55351295663786E-15 |
| Normal-vs-Age(81-100Yrs) |
1.557140E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.766800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.475600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.719600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.055040E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.108200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.137400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.835800E-03 |
| Classical-VS-Follicular |
4.00710000000304E-05 |
| Classical-VS-Other |
6.432800E-01 |
| Classical-VS-Normal |
3.4107050517207E-11 |
| Tall-VS-Follicular |
1.781580E-01 |
| Tall-VS-Other |
3.535800E-01 |
| Tall-VS-Normal |
2.42250663973209E-13 |
| Follicular-VS-Other |
9.762100E-02 |
| Follicular-VS-Normal |
1.62436730732907E-12 |
| Other-VS-Normal |
1.106010E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.43849426498855E-15 |
| Normal-vs-N1 |
2.81441536742477E-13 |
| N0-vs-N1 |
8.902000E-01 |
|
|
